The estimated Net Worth of Chris A Rallis is at least $400 Mille dollars as of 5 July 2024. Mr. Rallis owns over 1,792 units of Fennec Pharmaceuticals Inc stock worth over $250,534 and over the last 8 years he sold FENC stock worth over $23,102. In addition, he makes $126,652 as Independent Director at Fennec Pharmaceuticals Inc.
Chris has made over 16 trades of the Fennec Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 1,792 units of FENC stock worth $5,000 on 5 July 2024.
The largest trade he's ever made was exercising 17,592 units of Fennec Pharmaceuticals Inc stock on 8 March 2022 worth over $10,027. On average, Chris trades about 3,132 units every 40 days since 2016. As of 5 July 2024 he still owns at least 47,630 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Mr. Rallis stock trades at the bottom of the page.
Chris A. Rallis serves as Independent Director of the Company. Mr. Rallis has been an executive-in-residence at Pappas Capital, a life science venture capital firm since January 2008. Previously, Mr. Rallis was the President and Chief Executive Officer of ImmunoBiosciences, Inc. (“IBI”), a vaccine technology company formerly located in Raleigh, North Carolina from April 2006 through June 2007. Prior to joining IBI, Mr. Rallis served as an executive in residence (part-time) for Pappas Capital, and as a consultant for Duke University and Panacos Pharmaceuticals, Inc. Mr. Rallis is the former President and Chief Operating Officer (“COO”) and director of Triangle Pharmaceuticals, Inc., which was acquired by Gilead Sciences in January 2003 for approximately $465 million. Prior to assuming the role of President and COO in March 2000, he was Executive Vice President, Business Development and General Counsel. While at Triangle, Mr. Rallis participated in 11 equity financings generating gross proceeds of approximately $500 million. He was also primarily responsible for all business development activities which included a worldwide alliance with Abbott Laboratories and the in-licensing of ten compounds. Before joining Triangle in 1995, Mr. Rallis served in various business development and legal management roles with Burroughs Wellcome Co. over a 13-year period, including Vice President of Strategic Planning and Business Development. Mr. Rallis also serves on the board of Tenax Therapeutics, Inc., a biopharmaceutical company located in Morrisville, North Carolina. Mr. Rallis received his A.B. degree in economics from Harvard College and a J.D. from Duke University. As a result of these and other professional experiences, Mr. Rallis possesses particular healthcare industry knowledge and experience which strengthens the Board’s collective qualifications, skills, and experience.
As the Independent Director of Fennec Pharmaceuticals Inc, the total compensation of Chris Rallis at Fennec Pharmaceuticals Inc is $126,652. There are 7 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.
Chris Rallis is 63, he's been the Independent Director of Fennec Pharmaceuticals Inc since 2011. There are 2 older and 6 younger executives at Fennec Pharmaceuticals Inc. The oldest executive at Fennec Pharmaceuticals Inc is Anne McKay, 67, who is the Regulatory Consultant.
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En... e Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include: